1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 21, 1996
IDEC PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-19311 33-0112644
(Commission File Number) (IRS Employer Identification No.)
11011 Torreyana Road, San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(619) 550-8500
(Registrant's telephone number, including area code)
2
Item 5. Other Events.
On May 21, 1996, IDEC Pharmaceuticals Corporation (the "Company")
entered into a letter agreement with Genentech, Inc., a copy of which is
attached hereto as Exhibit 10.1.
On May 22, 1996, the Company's shareholders approved the amendment of
the Company's Articles of Incorporation to increase the authorized number of
shares to 50,000,000. A copy of the Company's Second Amended and Restated
Articles of Incorporation, filed with the Secretary of State of the State of
California, is attached hereto as Exhibit 3.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
Exhibit 3.1 Second Amended and Restated Articles of
Incorporation
Exhibit 10.1 Letter Agreement between the Company and
Genentech, Inc., dated May 21, 1996.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IDEC PHARMACEUTICALS CORPORATION
By: /s/ PHILLIP M. SCHNEIDER
------------------------------------
Phillip M. Schneider, Vice President
and Chief Financial Officer
Date: June 6, 1996
-1-
3
EXHIBIT INDEX
Sequentially
Exhibit Numbered
Number Document Page
------ -------- -------------
3.1 Second Amended and Restated Articles of Incorporation . . . . . . . . __
10.1 Letter Agreement between the Company and Genentech, Inc., dated May
21, 1996 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . __
-2-